A dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer

O'Neill, V., Kaye, S., Reed, N., Paul, J. , Davis, J. and Vasey, P. (2002) A dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer. British Journal of Cancer, 86(9), pp. 1385-1390. (doi:10.1038/sj/bjc/6600259)

Full text not currently available from Enlighten.

Abstract

The docetaxel-carboplatin combination is active and well tolerated in patients with epithelial ovarian cancer. We added epirubicin to this combination to investigate additional benefits of anthracyclines in epithelial ovarian cancer. Twenty-one 2 patients, FlGO Ic-IV, performance status 0-1, were treated in four dose cohorts. Docetaxel was fixed at 75 mg m(-2), carboplatin doses were AUC 4-5 and epirubicin doses were 50-60 mg m(-2). Drugs were given on day 1, every 3 weeks, except in cohort 3, where epirubicin was given on day 8. Dexamethasone was given prophylactically. One dose-limiting toxicity occurred in cohorts 1, 2 and 4, two occurred in cohort 3. Complicated neutropenia occurred in two patients in cohorts 1 and 2 and one patient in cohorts 3 and 4, Two patients experienced grade III diarrhoea or stomatitis in cohort 1 and two in cohort 3. There were no treatment-related deaths. Grade II sensory neuropathy occurred in one patient. No cardiac toxicity or significant oedema was observed. The overall response rate was 36%, and 62% were CA125 responders. 2 The predefined maximum tolerated dose was exceeded in cohort 3. The cohort 4 dose level (epirubicin 50 mg m(-2), carboplatin AUC 4, docetaxel 75 mg m-2), warrants further study.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Paul, Mr James
Authors: O'Neill, V., Kaye, S., Reed, N., Paul, J., Davis, J., and Vasey, P.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:British Journal of Cancer
ISSN:0007-0920

University Staff: Request a correction | Enlighten Editors: Update this record